The Line

Trade war!

In the latest episode of The Line Podcast, recorded on August 28th, 2026, Matt Gurney and Jen Gerson begin with the rapidly escalating Canada-U.S. trade war, which somehow managed to get very stupid, very quickly. Ontario Premier Doug Ford told Donald Trump to kiss his ass; Trump responded by signing an executive order renaming Lake Ontario “Lake America.” Your hosts discuss just how weird this confrontation could get—and whether what we're watching now is merely the opening phase of something much longer and more serious. This episode is brought to you by Cameco. In nuclear energy, timelines and costs matter. Incomplete designs carry real risk of delays and cost overruns. That’s why the AP1000 reactor is the right choice for Canada: it is already operating today and ready now to deliver the power we need, with 100 percent Canadian ownership and strong participation from Canadian suppliers. If we are serious about building Canada and powering it on time and on budget, the choice is clear. The AP1000 reactor is the only option that delivers. To learn more, visit ap1000.cameco.com Next, Matt and Jen argue that Canada still needs to get much better at fighting the communications and information war. The United States has recently confronted Chinese influence operations aimed at shaping its domestic politics, which raises an uncomfortable question: how confident should Canadians be that nobody is trying the same thing here? And if information operations are becoming a normal instrument of state power, should Canada be thinking seriously about developing the capacity to play offence as well as defence? This episode is also brought to you by Fractional Execs Canada. Need help with a serious business problem? As Canadian businesses grow they often require expert help to solve key business challenges. Fractional Execs Canada have assembled a team of experienced strategists, implementers, sales and marketing operators that can help transform your business into a growth engine. They match you with the right person, or team to move your business forward at a pace your business can manage. Talk to Fractional Execs Canada and discover a better, more collaborative way to take your business and your ‘busyness’ in a better direction. Canadian expertise to support the growth of Canadian businesses. Build your business with those that know how. Find them Fractional-Execs.ca. Finally, your hosts turn to a CBC controversy that sounds considerably crazier in the headlines than it actually is. CBC's longstanding journalistic policy is to avoid independently designating particular acts as “terrorism,” preferring to use the term with attribution—a policy shared in various forms by several major international news organizations. But an internal reminder applying that rule to the 9/11 attacks has predictably exploded into a controversy suggesting that Canada's public broadcaster somehow doesn't believe 9/11 was terrorism. Matt and Jen explain why the underlying policy isn't nearly as stupid as it looks—and also why, in this particular case, it's still dumb enough that CBC should fix it. This episode is also brought to you by BioCanRx. Through our partnership with federally-funded Canadian not-for-profit BioCanRx this summer, we’re talking about potential solutions for the problems that are limiting Canada’s ability to domestically develop new drugs, especially immunotherapies for cancer. Today: new methods for biomanufacturing. Immunotherapies are created using living components –– sometimes even our own cells — so they’re extremely complex and costly to create and deliver to patients. That’s why in the United States, only one in five people who could be treated by a personalized therapy like CAR T can afford to receive it. Fortunately, new manufacturing paradigms have the potential to increase accessibility. Similar to how 3D printers can efficiently produce individual mechanical components, closed-system manufacturing creates immunotherapy drugs in self-contained, benchtop machines that enhance efficiency through automation. This turns many hospitals across Canada into potential manufacturing sites and makes scaling up the delivery of personalized therapies to individual Canadian patients a real possibility. Some new manufacturing technologies can even scale from producing a single patient’s personalized dose to mass-producing doses for 100,000 patients per day — meaning they could mass-produce vaccines during an emergency. BioCanRx is working with federal partners to understand where this technology can fit within our biomanufacturing regulatory structure, and how AI might help. More on that next time. Learn more at BioCanRx.com. All that and more in the latest episode of The Line Podcast. #TheLinePodcast #CanadaUSRelations #DonaldTrump #DougFord #MarkCarney #TradeWar #ForeignInterference #CBC #CanadianPolitics #CurrentAffairs

• Chapters

No Religion Allowed in the Canadian Military

In this episode of On The Line, Jen Gerson sits down with Brian Dijkema, president of Cardus Canada, to discuss a new Department of National Defence directive that would move military chaplaincy away from explicit religious language, symbols and prayer in favour of more generic forms of “spiritual reflection.” This episode is brought to you by BioCanRx. Through our partnership with federally-funded Canadian not-for-profit BioCanRx this summer, we’re talking about potential solutions for the problems that are limiting Canada’s ability to domestically develop new drugs, especially immunotherapies for cancer. Today: new methods for biomanufacturing. Immunotherapies are created using living components –– sometimes even our own cells –– so they're extremely complex and costly to create and deliver to patients. That's why in the United States, only one in five people who could be treated by a personalized therapy like CAR T can afford to receive it. Fortunately, new manufacturing paradigms have the potential to increase accessibility. Similar to how 3D printers can efficiently produce individual mechanical components, closed-system manufacturing creates immunotherapy drugs in self-contained, benchtop machines that enhance efficiency through automation. This turns many hospitals across Canada into potential manufacturing sites and makes scaling up the delivery of personalized therapies to individual Canadian patients a real possibility. Some new manufacturing technologies can even scale from producing a single patient’s personalized dose to mass-producing doses for 100,000 patients per day –– meaning they could mass-produce vaccines during an emergency. BioCanRx is working with federal partners to understand where this technology can fit within our biomanufacturing regulatory structure, and how AI might help. More on that next time. Learn more at BioCanRx.com. Dijkema argues that the change isn’t actually neutral. Instead, he sees it as part of a longer-running bureaucratic effort to reduce the visible role of religion within the Canadian Armed Forces. He and Gerson dig into the philosophical question at the heart of the dispute: is secular humanism really a neutral baseline for a diverse society, or is it itself a worldview that the state risks imposing on everyone else? They also talk about what military chaplains actually do. Dijkema argues that chaplains serve a special purpose. Questions about death, war, morality and meaning are not simply clinical problems, and military personnel should have access to people capable of engaging with them through their own religious traditions. This episode is also brought to you by the Forest Products Association of Canada. Canada’s resilience will not be built through diversified trade and good intentions alone. It will be built with strong domestic supply chains, reliable Canadian materials, and industries that invest in workers and communities here at home. Two months ago, the federal government acknowledged the Forest Sector Transformation Task Force Report and the practical path it set out. Now the focus must be action. Canada’s forest products sector can help deliver the homes, infrastructure, and economic potential the country needs. But that requires predictable access to manage our forests, transportation systems that work, and a regulatory environment that rewards investment rather than delays it. The direction is clear. Now Ottawa needs to turn recognition into results. Learn more at FPAC.ca. Gerson and Dijkema also examine the directive’s special treatment of Indigenous spiritual practices, which Dijkema argues is both logically inconsistent and ultimately patronizing. His preferred alternative is straightforward: expand the space available to religious and non-religious Canadians alike rather than trying to make everyone conform to a supposedly neutral middle ground. This episode is brought to you by Cameco. In nuclear energy, timelines and costs matter. Incomplete designs carry real risk of delays and cost overruns. That’s why the AP1000 reactor is the right choice for Canada: it is already operating today and ready now to deliver the power we need, with 100 percent Canadian ownership and strong participation from Canadian suppliers. If we are serious about building Canada and powering it on time and on budget, the choice is clear. The AP1000 reactor is the only option that delivers. To learn more, visit ap1000.cameco.com. Check out our main page at ReadTheLine.ca, and as always, like and subscribe. #OnTheLine #CanadianForces #MilitaryChaplaincy #ReligiousFreedom #Pluralism #BrianDijkema #Cardus #CanadaPolitics #CanadianMilitary #JenGerson

• Chapters

If the deal sucks, Carney is in trouble

In the latest episode of The Line Podcast, recorded on August 21st, 2026, Matt Gurney joins remotely from Chicago as he makes his way home to Canada after a family event. Sorry, elbows uppers. This episode is brought to you by Cameco. In nuclear energy, timelines and costs matter. Incomplete designs carry real risk of delays and cost overruns. That’s why the AP1000 reactor is the right choice for Canada: it is already operating today and ready now to deliver the power we need, with 100 percent Canadian ownership and strong participation from Canadian suppliers. If we are serious about building Canada and powering it on time and on budget, the choice is clear. The AP1000 reactor is the only option that delivers. To learn more, visit ap1000.cameco.com The first segment is, admittedly, a bit of a placeholder. Until there is an actual Canada-U.S. trade deal to read, it's difficult to have firm opinions about it — assuming there even is a deal. Your hosts walk through what's been reported so far and explain why they're reserving judgment until the details are public. That said, Matt highlights one rumoured provision that, if true, would represent a uniquely Canadian style of spectacularly self-inflicted policy failure. For the deeper analysis, look for Sunday's Dispatch. This episode is also brought to you by Fractional Execs Canada. Need help with a serious business problem? As Canadian businesses grow they often require expert help to solve key business challenges. Fractional Execs Canada have assembled a team of experienced strategists, implementers, sales and marketing operators that can help transform your business into a growth engine. They match you with the right person, or team to move your business forward at a pace your business can manage. Talk to Fractional Execs Canada and discover a better, more collaborative way to take your business and your ‘busyness’ in a better direction. Canadian expertise to support the growth of Canadian businesses. Build your business with those that know how. Find them Fractional-Execs.ca. Next, Matt and Jen examine the early political reaction to both the negotiations themselves and the rumours surrounding the deal. Both were struck by comments this week from Manitoba Premier Wab Kinew. With a combination of clarity and folksy charm, Kinew articulated what your hosts believe is the strongest criticism of Mark Carney's handling of the America file they've heard so far. They're not suggesting Kinew is about to jump into federal politics. He doesn't need to. If someone can make a compelling case that this deal is bad for Canada, Carney could find himself under pressure from both the left and the right. This episode is also brought to you by BioCanRx. Through our partnership with federally-funded Canadian not-for-profit BioCanRx this summer, we’re talking about potential solutions for the problems that limit Canada’s ability to domestically develop new drugs, especially immunotherapies for cancer. Today: Canada’s biomanufacturing capacity. A biomanufacturing industry, like any other industry, does not appear at the swipe of a bureaucrat’s pen. Simply allocating money to a new economic development program doesn’t replace the years of effort necessary to help a sector put down lasting roots. Canada already has many building blocks in place. For example, infrastructure developed for pandemic readiness after COVID, and money invested in research facilities across Canada, can be leveraged to give us a head start — but they need to be coordinated and given steady work. BioCanRx supports core Canadian biomanufacturing facilities and connects them with active Canadian research projects, making sure both sides have resources and the chance to gain experience. But more activity is needed to ensure these facilities can build up expertise, maintain readiness, and foster innovation. Building this capacity can position Canada to develop new drugs more quickly — and to be ready for a health emergency, all while delivering products to Canadian patients today. There are promising paradigm shifts on the horizon that could change the way we manufacture biologic products like immunotherapies. More on that next week. Visit BioCanRx.com to learn more. Finally, Matt reflects on his recent travels through the United States. There are many ways Canada will never compete directly with America — they're simply bigger and richer. But there are also areas where Canada once had a visible edge and has quietly lost it. Chicago has always had more crime and a higher murder rate than Toronto. That's nothing new. What is new, Matt argues, is that downtown Chicago is now noticeably cleaner and better maintained than downtown Toronto. That's not a consequence of American military power, economic dominance, or Donald Trump. That's a Canadian policy failure. And the really damning part? Downtown Detroit is cleaner than Toronto now, too. All that and more in the latest episode of The Line Podcast. Check out our main page at ReadTheLine.ca. Like and subscribe! #TheLinePodcast #MarkCarney #CanadaUSRelations #TradeDeal #CanadianPolitics #WabKinew #Toronto #Chicago #PoliticalAnalysis #CurrentAffairs

• Chapters

It's time for Canada to abandon a cherished national myth

In this episode of On The Line, host Matt Gurney is joined by two guests for conversations about service, sacrifice, and Canada’s place in the world. This episode is brought to you by BioCanRx. Through our partnership with federally-funded Canadian not-for-profit BioCanRx this summer, we’re talking about potential solutions for the problems that limit Canada’s ability to domestically develop new drugs, especially immunotherapies for cancer. Today: Canada’s biomanufacturing capacity. A biomanufacturing industry, like any other industry, does not appear at the swipe of a bureaucrat’s pen. Simply allocating money to a new economic development program doesn’t replace the years of effort necessary to help a sector put down lasting roots. Canada already has many building blocks in place. For example, infrastructure developed for pandemic readiness after COVID, and money invested in research facilities across Canada, can be leveraged to give us a head start –– but they need to be coordinated and given steady work. BioCanRx supports core Canadian biomanufacturing facilities and connects them with active Canadian research projects, making sure both sides have resources and the chance to gain experience. But more activity is needed to ensure these facilities can build up expertise, maintain readiness, and foster innovation. Building this capacity can position Canada to develop new drugs more quickly –– and to be ready for a health emergency, all while delivering products to Canadian patients today. There are promising paradigm shifts on the horizon that could change the way we manufacture biologic products like immunotherapies. More on that next week. Visit BioCanRx.com to learn more. First up is Anthony Robb, a 24-year veteran of the Canadian Army who now serves with Canada Company. He joins Matt to discuss the organization’s work strengthening the connection between Canadians and their military, and why that relationship matters more than ever. They also talk about one of Canada Company’s most meaningful initiatives: supporting the children of Canadian Armed Forces members who made the ultimate sacrifice in service to their country, and ensuring those families know their sacrifices have not been forgotten. This episode is also brought to you by the Forest Products Association of Canada. Canada’s resilience will not be built through diversified trade and good intentions alone. It will be built with strong domestic supply chains, reliable Canadian materials, and industries that invest in workers and communities here at home.Two months ago, the federal government acknowledged the Forest Sector Transformation Task Force Report and the practical path it set out. Now the focus must be action. Canada’s forest products sector can help deliver the homes, infrastructure, and economic potential the country needs. But that requires predictable access to manage our forests, transportation systems that work, and a regulatory environment that rewards investment rather than delays it. The direction is clear. Now Ottawa needs to turn recognition into results. Learn more at FPAC.ca. Then Matt is joined by Peter Jones, professor of international relations at the University of Ottawa, for a conversation about one of Canada’s most enduring national stories. Canadians often describe their country as a “middle power,” but Jones argues that label hasn’t accurately described Canada for quite some time. If we aren’t a middle power anymore, what are we? And, more importantly, what should we aspire to be in a world that is becoming less stable, more competitive, and increasingly defined by great-power rivalry? For more on the professor's thoughts on this topic, please read his recent essay in The Walrus. This episode is brought to you by Cameco. In nuclear energy, timelines and costs matter. Incomplete designs carry real risk of delays and cost overruns. That’s why the AP1000 reactor is the right choice for Canada: it is already operating today and ready now to deliver the power we need, with 100 percent Canadian ownership and strong participation from Canadian suppliers. If we are serious about building Canada and powering it on time and on budget, the choice is clear. The AP1000 reactor is the only option that delivers. To learn more, visit ap1000.cameco.com. If you like this — or hey, even if you hated it, we don't mind — check out our main page at ReadTheLine.ca. Be sure to like and subscribe! #OnTheLine #CanadaCompany #CanadianForces #Veterans #AnthonyRobb #PeterJones #ForeignPolicy #CanadaPolitics #NationalSecurity #MattGurney

• Chapters

Carney can fight now, or he should surrender

In the latest episode of The Line Podcast, recorded on August 14th, 2026, Matt Gurney and Jen Gerson begin with a lengthy discussion of the state of the Canada–U.S. trade war. This episode is brought to you by Cameco. In nuclear energy, timelines and costs matter. Incomplete designs carry real risk of delays and cost overruns. That’s why the AP1000 reactor is the right choice for Canada: it is already operating today and ready now to deliver the power we need, with 100 percent Canadian ownership and strong participation from Canadian suppliers. If we are serious about building Canada and powering it on time and on budget, the choice is clear. The AP1000 reactor is the only option that delivers.To learn more, visit ap1000.cameco.com Your hosts are in complete agreement: Canada should not accept a bad deal. A bad deal wouldn't buy lasting peace, they argue — it would simply set the stage for the next round of American demands. In their view, there is no stable middle ground. Canada either resists now or surrenders now. They also examine the unusual political psychology of the Americans currently running the White House, while cautioning listeners not to expect salvation from the Democrats. A future Democratic administration may be less abrasive, but it won't undo the underlying shift in American policy. As Matt puts it, quoting the late Chris Cornell, "Arm yourselves because no one else here will save you." That includes the likes of Gavin Newsom and Chuck Schumer. This episode is also brought to you by Fractional Execs Canada. Need help with a serious business problem? As Canadian businesses grow they often require expert help to solve key business challenges. Fractional Execs Canada have assembled a team of experienced strategists, implementers, sales and marketing operators that can help transform your business into a growth engine. They match you with the right person, or team to move your business forward at a pace your business can manage. Talk to Fractional Execs Canada and discover a better, more collaborative way to take your business and your ‘busyness’ in a better direction. Canadian expertise to support the growth of Canadian businesses. Build your business with those that know how. Find them Fractional-Execs.ca. From there, the hosts turn to Alberta and a fascinating Toronto Star investigation tracking the flow of money supporting the separatist movement. The reporting closely matches what both Line editors had already concluded independently. Jen offers an update from the ground in Alberta, while Matt steps back to consider the national implications. Both arrive at the same frustrating conclusion: it would be helpful if Canada's institutions were capable of recognizing foreign interference when it was happening. Recent history suggests we're not only bad at it — we don't even seem particularly interested in trying. Finally, Matt and Jen close with a friendly disagreement over the controversy surrounding Prime Minister Mark Carney's vacation in Italy. They don't see eye to eye, and by the end of the conversation it's clear Matt is unlikely to invite Jen along on his next European vacation. If you'd like to help fund that hypothetical trip, your hosts suggest the usual: like, subscribe, and donate generously. This episode is brought to you by BioCanRx, a federally-funded Canadian not-for-profit. This summer, BioCanRx and The Line have been talking about potential solutions for the problems that are limiting Canada’s ability to domestically develop new drugs, especially immunotherapies for cancer. We ask a lot of Canadian cancer researchers. The work required to discover new therapies for numerous diseases, and get them to patients, costs far more than the half-billion dollars invested in cancer research by all levels of government and charities — and often the available grants specialize in only one part of the spectrum: discovery. We need to be sure we’re supporting researchers at every step of this complex scientific and regulatory process. BioCanRx has proved you can meaningfully support this part. The entire team is only 12 people, but they know what it takes to do things like submit a clinical trial application or safely manufacture a drug, so the researchers they fund are held to firm, realistic standards that make sense in the real world of Canadian health-care systems and industry. That’s how a tiny not-for-profit has helped bring 16 new drugs to clinical trials that have treated more than 400 people in just 10 years. But research is only one part of the puzzle — can we manufacture new therapies in Canada? More on that next time. Visit BioCanRx.com to learn more. All that and more in the latest episode of The Line Podcast. #TheLinePodcast #MarkCarney #CanadaUSRelations #TradeWar #CanadianPolitics #AlbertaPolitics #ForeignInterference #GavinNewsom #ChuckSchumer #CurrentAffairs

• Chapters

Is Alberta hurtling toward the edge?

In this episode of On The Line, host Jen Gerson sits down with Jared Wesley and Ken Boessenkool, two members of the Lead Not Leave initiative, for a conversation about the current state of Alberta separatism and the province’s uncertain political future. This episode is brought to you by BioCanRx, a federally-funded Canadian not-for-profit. This summer, BioCanRx and The Line have been talking about potential solutions for the problems that are limiting Canada’s ability to domestically develop new drugs, especially immunotherapies for cancer. We ask a lot of Canadian cancer researchers. The work required to discover new therapies for numerous diseases, and get them to patients, costs far more than the half-billion dollars invested in cancer research by all levels of government and charities –– and often the available grants specialize in only one part of the spectrum: discovery. We need to be sure we're supporting researchers at every step of this complex scientific and regulatory process. BioCanRx has proved you can meaningfully support this part. The entire team is only 12 people, but they know what it takes to do things like submit a clinical trial application or safely manufacture a drug, so the researchers they fund are held to firm, realistic standards that make sense in the real world of Canadian health-care systems and industry. That’s how a tiny not-for-profit has helped bring 16 new drugs to clinical trials that have treated more than 400 people in just 10 years. But research is only one part of the puzzle — can we manufacture new therapies in Canada? More on that next time. Visit BioCanRx.com to learn more. While recent polling has suggested that support for outright separation may be softer than some headlines imply, neither Wesley nor Boessenkool is particularly sanguine about the outcome of the coming referendum campaign. They argue that low turnout and voter suppression could produce a result that overstates support for separatism, creating a misleading picture of where Albertans actually stand. The discussion also examines the changing relationship between Alberta and Ottawa, and whether recent improvements between the provincial and federal governments have meaningfully reduced the political grievances that have fuelled separatist sentiment. They explore the concept of moral hazard in Canadian federalism, the incentives facing provincial leaders, and whether those dynamics are helping—or hurting—the cause of national unity. This episode is also brought to you by the Forest Products Association of Canada. Canada’s resilience will not be built through diversified trade and good intentions alone. It will be built with strong domestic supply chains, reliable Canadian materials, and industries that invest in workers and communities here at home.Two months ago, the federal government acknowledged the Forest Sector Transformation Task Force Report and the practical path it set out. Now the focus must be action. Canada’s forest products sector can help deliver the homes, infrastructure, and economic potential the country needs. But that requires predictable access to manage our forests, transportation systems that work, and a regulatory environment that rewards investment rather than delays it. The direction is clear. Now Ottawa needs to turn recognition into results.Learn more at FPAC.ca. Finally, Gerson asks what happens after the vote. Whatever the result, will the United Conservative Party be able to hold together, or are the internal tensions that have defined Alberta conservatism for years becoming too great to contain? As always, check out our main page at ReadTheLine.ca — and never, ever forget to like and subscribe! This episode is brought to you by Cameco. In nuclear energy, timelines and costs matter. Incomplete designs carry real risk of delays and cost overruns. That’s why the AP1000 reactor is the right choice for Canada: it is already operating today and ready now to deliver the power we need, with 100 percent Canadian ownership and strong participation from Canadian suppliers. If we are serious about building Canada and powering it on time and on budget, the choice is clear. The AP1000 reactor is the only option that delivers.To learn more, visit ap1000.cameco.com. #OnTheLine #Alberta #AlbertaPolitics #Separatism #LeadNotLeave #JaredWesley #KenBoessenkool #CanadaPolitics #JenGerson #TheLinePodcast

• Chapters

How many times can Carney concede to Trump? (Probably lots)

In the latest episode of The Line Podcast, recorded on August 7th, 2026, Matt Gurney is joined by guest host Scott Stinson, filling in for Jen Gerson. They begin with the latest twists in Canada-U.S. relations, asking just how much Prime Minister Mark Carney can concede to the Americans before the political costs become too high at home. Both hosts suspect the answer is probably more than many Canadians would expect. They also discuss how fortunate Carney is to be making these decisions while facing relatively weak opposition, with Pierre Poilievre enduring another difficult week. Matt explains why the Conservative leader continues to struggle to gain traction. This episode is brought to you by Cameco. In nuclear energy, timelines and costs matter. Incomplete designs carry real risk of delays and cost overruns. That’s why the AP1000 reactor is the right choice for Canada: it is already operating today and ready now to deliver the power we need, with 100 percent Canadian ownership and strong participation from Canadian suppliers. If we are serious about building Canada and powering it on time and on budget, the choice is clear. The AP1000 reactor is the only option that delivers. To larn more, visit ap1000.cameco.com. The conversation then shifts to Ontario politics, where many of the same themes are playing out. It should be a quiet summer at Queen’s Park, but instead the Ford government finds itself taking hits from all directions, including from an opposition party that doesn’t currently have a permanent leader. Matt and Scott discuss why the Ontario NDP appears so adrift. New Democratic governments are commonplace elsewhere in Canada, so why does the party remain unable to break through in Ontario, even with Doug Ford leading the PCs and the Liberals still searching for direction? Matt has a theory. This episode is also brought to you by Fractional Execs Canada. Need help with a serious business problem? As Canadian businesses grow they often require expert help to solve key business challenges. Fractional Execs Canada have assembled a team of experienced strategists, implementors, sales and marketing operators that can help transform your business into a growth engine. They match you with the right person, or team to move your business forward at a pace your business can manage. Talk to Fractional Execs Canada and discover a better, more collaborative way to take your business and your ‘busyness’ in a better direction. Canadian expertise to support the growth of Canadian businesses. Build your business with those that know how. Find them Fractional-Execs.ca. Finally, Scott brings listeners up to speed on the growing controversy surrounding Gianni Infantino and FIFA. The discussion broadens into a look at why major sports organizations seem almost inevitably to attract corruption—and why it’s so fascinating to watch the rare moments when those organizations actually decide to push back. This episode is also brought to you by BioCanRx, a Canadian not-for-profit working to help Canadian researchers and companies develop new drugs, especially immunotherapies for cancer. A key challenge for Canada will be familiar to anyone trying to grow a business here: we have some of the brightest people in the world, we just can’t keep enough of them. Canada is home to researchers making breakthrough discoveries every day. But bringing a new therapy from the lab to patients takes more than great science. It also requires specialists who know how to manufacture complex products, navigate regulatory approval, and help new treatments be integrated into the health-care system. Too often, that expertise leaves Canada before the work is done. BioCanRx has supported hands-on training for more than 900 trainees over the past decade, but without a strong domestic industry, retention becomes a challenge. So how do we keep these highly-skilled people? Next time we’ll talk about how changing what we incentivize can maximize the impact of research money Canada already spends to sustain more drug development here in Canada. For now, go to BioCanRx.com to learn more. All that and more in the latest episode of The Line Podcast. CHAPTERS 00:00 Intro 01:37 Can Carney keep conceding? (Yup!) 26:39 Fall of Ford 48:34 FIFA WTF #TheLinePodcast #MarkCarney #CanadianPolitics #CanadaUSRelations #PierrePoilievre #DougFord #OntarioPolitics #FIFA #GianniInfantino #CurrentAffairs

How to fix the West's ammunition shortage

In this episode of On The Line, host Matt Gurney is joined by two guests for conversations about two of the West's most pressing security challenges: military readiness and cyber defence. This episode is brought to you by BioCanRx, a Canadian not-for-profit working to help Canadian researchers and companies develop new drugs, especially immunotherapies for cancer. A key challenge for Canada will be familiar to anyone trying to grow a business here: we have some of the brightest people in the world, we just can’t keep enough of them. Canada is home to researchers making breakthrough discoveries every day. But bringing a new therapy from the lab to patients takes more than great science. It also requires specialists who know how to manufacture complex products, navigate regulatory approval, and help new treatments be integrated into the health-care system. Too often, that expertise leaves Canada before the work is done. BioCanRx has supported hands-on training for more than 900 trainees over the past decade, but without a strong domestic industry, retention becomes a challenge. So how do we keep these highly-skilled people? Next time we’ll talk about how changing what we incentivize can maximize the impact of research money Canada already spends to sustain more drug development here in Canada. For now, go to BioCanRx.com to learn more. First up is Mark Cancian of the Center for Strategic and International Studies, a retired U.S. Marine Corps colonel and one of the authors of a new report examining the alarming state of Western ammunition stockpiles. Drawing on the lessons of the wars in Ukraine and the Persian Gulf, Cancian explains how the United States and its allies are consuming critical munitions far faster than they can replace them. The West still possesses enormous military strength, but rebuilding industrial capacity has become an urgent strategic priority. Matt and Mark discuss what's driving the shortages, what governments are finally getting right, and why there are at least a few encouraging signs that production is beginning to catch up. This episode is also brought to you by the Forest Products Association of Canada. Canada’s resilience will not be built through diversified trade and good intentions alone. It will be built with strong domestic supply chains, reliable Canadian materials, and industries that invest in workers and communities here at home. Two months ago, the federal government acknowledged the Forest Sector Transformation Task Force Report and the practical path it set out. Now the focus must be action. Canada’s forest products sector can help deliver the homes, infrastructure, and economic potential the country needs. But that requires predictable access to manage our forests, transportation systems that work, and a regulatory environment that rewards investment rather than delays it. The direction is clear. Now Ottawa needs to turn recognition into results. Learn more at FPAC.ca. Then Matt is joined by David Shipley of Beauceron Security to discuss a coordinated cyberattack that recently struck a series of public utilities across the United States, causing real disruption to critical infrastructure. They examine who may have been behind the attacks, why utilities remain such attractive targets, and what governments and operators can do to improve their defences. The conversation also turns to whether growing political dysfunction in Washington is making it harder for the United States—and by extension its allies—to respond effectively to increasingly sophisticated cyber threats. It's a pair of conversations about resilience, preparedness, and the growing realization that winning future conflicts will depend as much on industrial capacity and digital security as on military hardware alone. This episode is brought to you by Cameco. In nuclear energy, timelines and costs matter. Incomplete designs carry real risk of delays and cost overruns. That’s why the AP1000 reactor is the right choice for Canada: it is already operating today and ready now to deliver the power we need, with 100 percent Canadian ownership and strong participation from Canadian suppliers. If we are serious about building Canada and powering it on time and on budget, the choice is clear. The AP1000 reactor is the only option that delivers. To learn more, visit ap1000.cameco.com. As always, check out our main page at ReadTheLine.ca, and don't forget to like and subscribe. #OnTheLine #MarkCancian #DavidShipley #CyberSecurity #NationalSecurity #Defense #Military #CSIS #CriticalInfrastructure #MattGurney

• Chapters

Have Carney and the rest given up on Canada already?

In the latest episode of The Line Podcast, recorded on July 31st, 2026, Matt Gurney and Jen Gerson begin by asking whether Canada's governments are actually prepared to make the sacrifices required to defend the country's interests. Both come away disappointed. Matt points to the federal government's decision to block the expansion of an airport in the Toronto area because it was locally controversial and could complicate an upcoming Liberal byelection. If a government isn't willing to risk losing even a single seat to get important things done, Matt argues, then it's never going to get important things done. This episode is brought to you by Cameco. In nuclear energy, timelines and costs matter. Incomplete designs carry real risk of delays and cost overruns. That’s why the AP1000 reactor is the right choice for Canada: it is already operating today and ready now to deliver the power we need, with 100 percent Canadian ownership and strong participation from Canadian suppliers. If we are serious about building Canada and powering it on time and on budget, the choice is clear. The AP1000 reactor is the only option that delivers. To learn more, visit ap1000.cameco.com. Next, Jen checks in from Alberta with an update on the separatist movement. While recent polling shows federalist forces comfortably ahead, she's far from reassured. The problem isn't the raw level of support for separation, which remains relatively low. It's the intensity. Separatists are deeply motivated, while federalists may assume victory is inevitable and fail to organize or even show up. If that happens, Jen warns, the result could be much closer than today's polls suggest. This episode is also brought to you by BioCanRx, a federally-funded Canadian not-for-profit research network dedicated to cutting edge cancer immunotherapy research that they’re helping Canadian researchers bring from labs to patients in clinical trials — all in Canada.If a drug is discovered in a Canadian lab, and conducts successful clinical trials in Canada, there’s a chance it will be launched in Canada. So how do we get more drugs out of Canadian labs and keep them here? Every year around $500 million is spent on Canadian cancer research, but 70 per cent of that is for early-stage work — discovering whether a therapy can do something in the lab. That leaves limited resources for the complex and often disjointed process of moving Canadian innovations from discovery to a clinical trial and hopefully into the health system.BioCanRx has stepped into the gap. They specialize in “translational research” — the unsexy work that makes for boring press releases, but gets results: 16 Canadian cancer immunotherapy clinical trials in just a decade, treating more than 400 patients.Thanks to this, BioCanRx has first-hand experience with the systemic disconnects that are trapping discoveries in Canadian labs, or sending them out of the country to be developed. They have straightforward ideas about how to fix the problems, and spoiler alert: the answer isn’t just “add more money.” Stay tuned to learn more in coming weeks, and visit BioCanRx.com to learn more. Finally, Matt raises reports about Jagmeet Singh's possible next job after politics, and he's unimpressed. Jen offers a different perspective, suggesting that perhaps there's something to be said for a political class that takes care of its own after public service. Your hosts don't reach a firm conclusion — but they lay out both sides and leave it to listeners to decide. All that and more in the latest episode of The Line Podcast. Check out our main page at ReadTheLine.ca. #TheLinePodcast #CanadianPolitics #MarkCarney #AlbertaPolitics #Federalism #JagmeetSingh #LiberalParty #PoliticalAnalysis #CanadaPolitics #CurrentAffairs

• Chapters

Is NATO Doomed? (And Canada along with it?)

For decades, Canada has enjoyed the benefits of NATO while spending comparatively little on its own military. That era may be coming to an end. This episode is brought to you by BioCanRx, a federally-funded Canadian not-for-profit research network dedicated to cutting edge cancer immunotherapy research that they’re helping Canadian researchers bring from labs to patients in clinical trials –– all in Canada. If a drug is discovered in a Canadian lab, and conducts successful clinical trials in Canada, there’s a chance it will be launched in Canada. So how do we get more drugs out of Canadian labs and keep them here? Every year around $500 million is spent on Canadian cancer research, but 70 per cent of that is for early-stage work –– discovering whether a therapy can do something in the lab. That leaves limited resources for the complex and often disjointed process of moving Canadian innovations from discovery to a clinical trial and hopefully into the health system. BioCanRx has stepped into the gap. They specialize in "translational research" –– the unsexy work that makes for boring press releases, but gets results: 16 Canadian cancer immunotherapy clinical trials in just a decade, treating more than 400 patients. Thanks to this, BioCanRx has first-hand experience with the systemic disconnects that are trapping discoveries in Canadian labs, or sending them out of the country to be developed. They have straightforward ideas about how to fix the problems, and spoiler alert: the answer isn’t just 'add more money." Visit BioCanRx.com to learn more. This week on On The Line, host Jen Gerson is joined by Jean-François Bélanger, Senior Non-Resident Associate Fellow at the NATO Defense College, for a wide-ranging discussion about Canada’s long-overdue military buildup and what it means for the future of the Alliance. Bélanger’s work focuses on deterrence, nuclear strategy, wargaming, multi-domain operations, and military decision-making, making him well placed to explain the strategic thinking behind today’s defence debates. As Ottawa commits to dramatically increasing defence spending, Gerson and Bélanger examine what those promises will actually require. Is Canada genuinely preparing for a more dangerous world, or simply catching up after decades of underinvestment? What capabilities do the Canadian Armed Forces need most urgently, and how should those investments be prioritized? The conversation also explores how NATO has evolved in recent years, how the Alliance has adapted to the return of Donald Trump to the White House, and what Canada’s role should be in an increasingly uncertain international environment. They discuss the growing strategic importance of the Arctic, the impact of emerging technologies on military planning, and how the character of warfare is changing. This episode is also brought to you by the Forest Products Association of Canada. Canada’s forest products sector is not asking Ottawa to start over. The federal government has heard the advice. It has recognized the challenges. And it has put a plan on the table. Now the test is action. That means clearing made-in-Canada barriers: regulatory duplication, transportation bottlenecks, and uncertainty around predictable access to manage our forests. It means working with provinces to protect communities from wildfire risk and giving companies the confidence to invest here at home. Nearly 200,000 Canadians working in this sector are looking for results. The playbook is written. Now Ottawa needs to deliver. Learn more at fpac.ca. Along the way, Bélanger explains why modern defence planning increasingly relies on forecasting, simulations, and sophisticated wargaming, and why many Canadians misunderstand both NATO’s purpose and Canada’s obligations within it. It’s a timely conversation about deterrence, alliance politics, and the difficult choices Canada faces as it prepares for a less stable world. For more, be sure to check out our main page at ReadTheLine.ca. Like and subscribe This episode is also brought to you by Cameco. In nuclear energy, timelines and costs matter. Incomplete designs carry real risk of delays and cost overruns. That’s why the AP1000 reactor is the right choice for Canada: it is already operating today and ready now to deliver the power we need, with 100 percent Canadian ownership and strong participation from Canadian suppliers. If we are serious about building Canada and powering it on time and on budget, the choice is clear. The AP1000 reactor is the only option that delivers. To learn more, visit ap1000.cameco.com. #OnTheLine #NATO #CanadaDefence #CanadianForces #JeanFrancoisBelanger #ArcticSecurity #Geopolitics #MilitaryStrategy #JenGerson #CanadaPolitics

• Chapters

Overworked Carney needlessly burns a bridge (get it?)

In the latest episode of The Line Podcast, recorded on July 24th, 2026, hosts Matt Gurney and Jen Gerson set out with the ambitious goal of keeping each segment to a specific, fixed time. They do not succeed. This episode is brought to you by BioCanRx, Ia federally-funded Canadian not-for-profit research network dedicated to cutting edge cancer immunotherapy research that they’re helping Canadian researchers bring from labs to patients in clinical trials –– all in Canada. If a drug is discovered in a Canadian lab, and conducts successful clinical trials in Canada, there’s a chance it will be launched in Canada. So how do we get more drugs out of Canadian labs and keep them here? Every year around $500 million is spent on Canadian cancer research, but 70 per cent of that is for early-stage work –– discovering whether a therapy can do something in the lab. That leaves limited resources for the complex and often disjointed process of moving Canadian innovations from discovery to a clinical trial and hopefully into the health system. BioCanRx has stepped into the gap. They specialize in "translational research" –– the unsexy work that makes for boring press releases, but gets results: 16 Canadian cancer immunotherapy clinical trials in just a decade, treating more than 400 patients. Thanks to this, BioCanRx has first-hand experience with the systemic disconnects that are trapping discoveries in Canadian labs, or sending them out of the country to be developed. They have straightforward ideas about how to fix the problems, and spoiler alert: the answer isn’t just 'add more money." Stay tuned to learn more in coming weeks, and visit BioCanRx.com to learn more. They begin by unpacking a remarkable week in Canada–U.S. relations. New details about the Gordie Howe Bridge agreement have emerged, and neither host likes what they see. Combined with another round of American tariffs, Jen argues that Prime Minister Mark Carney has committed his first major political fumble. Matt agrees that it's a setback, but also argues that the White House is undermining its own objectives. In an unusual role reversal, Matt even attempts to make the best possible case for Carney's strategy — despite having been the more hawkish voice in recent months. Jen isn't convinced. This episode is also brought to you by the Forest Products Association of Canada. Canada’s forest products sector is not asking Ottawa to start over. The federal government has heard the advice. It has recognized the challenges. And it has put a plan on the table. Now the test is action. That means clearing made-in-Canada barriers: regulatory duplication, transportation bottlenecks, and uncertainty around predictable access to manage our forests. It means working with provinces to protect communities from wildfire risk and giving companies the confidence to invest here at home. Nearly 200,000 Canadians working in this sector are looking for results. The playbook is written. Now Ottawa needs to deliver. Learn more at fpac.ca. The conversation then turns inward to Canadian politics. Jen argues that Carney is trying to do too many jobs himself. That observation leads both hosts to an amusing realization: Carney relies on his communications staff so infrequently that neither of them even knew who the key players were. Matt also argues that while the Conservatives remain effective at opposing the government on domestic issues, they're badly missing the mark on foreign affairs, and that's probably because they don't want to admit some things that they'd find awkward and unpleasant. Jen concludes that Canada really needs the Liberals' strategic instincts combined with the Conservatives' tactical effectiveness. Matt predicts, with characteristic optimism, that the country will somehow end up with neither. This episode is also brought to you by Cameco. In nuclear energy, timelines and costs matter. Incomplete designs carry real risk of delays and cost overruns. That’s why the AP1000 reactor is the right choice for Canada: it is already operating today and ready now to deliver the power we need, with 100 percent Canadian ownership and strong participation from Canadian suppliers. If we are serious about building Canada and powering it on time and on budget, the choice is clear. The AP1000 reactor is the only option that delivers. To learn more, visit ap1000.cameco.com. Finally, Matt ties together many of the themes from the episode by examining the recent arrest of a man alleged to have been involved in terrorism on behalf of Hamas against Canadian Jews. Matt simply walks through the timeline of the investigation and the eventual arrest. The chronology, he argues, speaks for itself. All that and more in the latest episode of The Line Podcast. #TheLinePodcast #MarkCarney #CanadianPolitics #CanadaUSRelations #TradeWar #GordieHoweBridge #PierrePoilievre #NationalSecurity #PoliticalAnalysis #CurrentAffairs

• Chapters

Our pollution attack on America has achieved total success

In the latest episode of The Line Podcast, recorded on July 17th, 2026, Matt Gurney and Jen Gerson keep things refreshingly brief as both are juggling family matters. They begin with Jen's unsuccessful attempt to achieve cottage zen, as she unloads on the latest complaints from American politicians about wildfire smoke drifting south from Canada. Both hosts independently arrive at the same tongue-in-cheek solution: if the Americans don't stop griping, Canada should simply schedule its forest fires for days when the wind is blowing south. (They're kidding. Mostly.) They also discuss Donald Trump's latest bizarre speech and the increasingly revealing comments from senior U.S. officials, who seem unable to hide just how much Prime Minister Mark Carney has gotten under their skin. This episode is brought to you by Fractional Execs Canada. Need help with a serious business problem? As Canadian businesses grow they often require expert help to solve key business challenges. Fractional Execs Canada have assembled a team of experienced strategists, implementors, sales and marketing operators that can help transform your business into a growth engine. They match you with the right person, or team to move your business forward at a pace your business can manage. Talk to Fractional Execs Canada and discover a better, more collaborative way to take your business and your ‘busyness’ in a better direction. Canadian expertise to support the growth of Canadian businesses. Build your business with those that know how. Find them Fractional-Execs.ca. Your hosts then turn to the slow-burning civil war within Canadian conservatism. Jen, still falling well short of cottage zen, has a few things to say. Matt observes that while Carney may be a practicing Catholic, he also seems to have accumulated an extraordinary amount of good karma in previous lives — politically speaking, he's facing remarkably little effective opposition from either the left or the right. Matt also warns the Conservatives that, whether they realize it or not, they're in danger of getting "Jagmeet Singhed." And it's not subtle. This episode is also brought to you by BioCanRx, a federally-funded Canadian not-for-profit research network focused on cutting-edge cancer immunotherapy research that they’re helping Canadian researchers bring from labs to patients in clinical trials –– all in Canada. A new treatment for your cancer has been approved. Can you get it? Maybe, maybe not. Canada isn’t just one health jurisdiction. At the federal level, Health Canada assesses the safety and efficacy of all drugs and therapies in the country, and in a year — sometimes less — they can approve one for sale in Canada. Once approved, — or sometimes while the assessment is happening— the drug’s cost effectiveness is evaluated by Canada’s Drug Agency. Then the ball goes to the provinces. They work together to negotiate prices with the drug maker, to confirm that it doesn’t duplicate something they’re already stocking, and that its potential value justifies its cost. Only after that can it be provided by each province’s ministry of health. This process can take years. It’s one reason that Canadian innovations leave the country to be developed elsewhere, and why drug companies don’t always choose Canada to initially to launch their products. In the U.S., they get FDA approval, set a price, and wait for the market to decide if the price is right. In Canada, Heath Canada approves and lengthy negotiations start, with no revenue or guarantee of future approval. Organizations like BioCanRx are willing to wait out the dry years because they’re not-for-profit, but companies with shareholders might skip the Canadian market until they’re making big money elsewhere. This means Canadians have to wait on the system for drugs that could save them, and are saving people in other countries. We’ll talk more about these problems in the weeks to come. Stay tuned for more. The hosts wrap up by discussing Naheed Nenshi's apology for speaking with an Israeli, which Matt suggests has elevated the Alberta NDP leader to full windbag status. Matt reminds Jen that he used to complain Nenshi needed to get himself into the public eye more often. After this week, he'd like to politely withdraw that recommendation. Jen wonders if maybe this is why he's been invisible — he might just actually be awful at this. Anyway, congrats to Danielle Smith. At this rate, she'll be premier for life. All that and more in the latest episode of The Line Podcast. Check out our main page at ReadTheLine.ca, and keep your kindling and torches ready. Wait for the code word. #TheLinePodcast #MarkCarney #CanadianPolitics #DonaldTrump #CanadaUSRelations #ConservativeParty #NaheedNenshi #AlbertaPolitics #PoliticalAnalysis #CurrentAffairs

• Chapters

Canada can build transportation gooder (and where we did build good)

In this episode of On The Line, host Matt Gurney sits down with Reece Martin, transit and transportation expert and new media entrepreneur, for a conversation about infrastructure, public policy, and how an online passion project turned into a career. This episode is brought to you by BioCanRx, a federally-funded Canadian not-for-profit research network focused on cutting-edge cancer immunotherapy research that they’re helping Canadian researchers bring from labs to patients in clinical trials –– all in Canada. A new treatment for your cancer has been approved. Can you get it? Maybe, maybe not. Canada isn’t just one health jurisdiction. At the federal level, Health Canada assesses the safety and efficacy of all drugs and therapies in the country, and in a year — sometimes less — they can approve one for sale in Canada. Once approved, — or sometimes while the assessment is happening— the drug's cost effectiveness is evaluated by Canada's Drug Agency. Then the ball goes to the provinces. They work together to negotiate prices with the drug maker, to confirm that it doesn't duplicate something they’re already stocking, and that its potential value justifies its cost. Only after that can it be provided by each province’s ministry of health. This process can take years. It’s one reason that Canadian innovations leave the country to be developed elsewhere, and why drug companies don’t always choose Canada initially to launch their products. In the U.S., they get FDA approval, set a price, and wait for the market to decide if the price is right. In Canada, Health Canada approves and lengthy negotiations start, with no revenue or guarantee of future approval. Organizations like BioCanRx are willing to wait out the dry years because they're not-for-profit, but companies with shareholders might skip the Canadian market until they’re making big money elsewhere. This means Canadians have to wait on the system for drugs that could save them, and are saving people in other countries. We’ll talk more about these problems in the weeks to come. Stay tuned for more. Martin explains how his fascination with transit and transportation grew into a successful YouTube channel, and how that work eventually made him a go-to commentator for conventional media on major infrastructure issues. They discuss the opportunities created by the new media landscape, the challenges of building an audience around complex policy topics, and why expertise can now emerge from outside traditional institutions. From there, the conversation turns to Canada’s infrastructure record. Matt and Jen often joke that “Canada no build good,” and Martin largely agrees — but with important caveats. He explains where Canada consistently goes wrong, why projects take so long and cost so much, and how political incentives often work against good long-term planning. This episode is also brought to you by the Forest Products Association of Canada. Canada’s forest products sector is not asking Ottawa to start over. The federal government has heard the advice. It has recognized the challenges. And it has put a plan on the table. Now the test is action. That means clearing made-in-Canada barriers: regulatory duplication, transportation bottlenecks, and uncertainty around predictable access to manage our forests. It means working with provinces to protect communities from wildfire risk and giving companies the confidence to invest here at home. Nearly 200,000 Canadians working in this sector are looking for results. The playbook is written. Now Ottawa needs to deliver. Learn more at fpac.ca. At the same time, Martin argues that Canada has real infrastructure success stories that deserve more attention. Rather than assuming failure is inevitable, governments should study the jurisdictions that consistently deliver major projects on time and on budget, both at home and abroad. If Canada can learn those lessons — and avoid the kinds of procurement failures that have plagued everything from pipelines to military equipment — our cities could finally get the transit systems they need. And yes, that conversation inevitably leads to the question every Canadian transit enthusiast eventually asks: will Canada actually build true high-speed rail? Be still, our beating hearts. Check out our main page at ReadTheLine.ca, and be sure to check out and follow Reece's YouTube channel and Substack, as well. This episode is also brought to you by Cameco. In nuclear energy, timelines and costs matter. Incomplete designs carry real risk of delays and cost overruns. That’s why the AP1000 reactor is the right choice for Canada: it is already operating today and ready now to deliver the power we need, with 100 percent Canadian ownership and strong participation from Canadian suppliers. If we are serious about building Canada and powering it on time and on budget, the choice is clear. The AP1000 reactor is the only option that delivers. To learn more, visit ap1000.cameco.com. YOUTUBE: https://www.youtube.com/c/RMTransit/videos SUBSTACK: https://www.thetransitbrief.net/

• Chapters

Carney is building a new post-America world

In the latest episode of The Line Podcast, recorded on July 10, 2026, Matt Gurney and Jen Gerson begin with a discussion of a recent Wall Street Journal piece highlighting Prime Minister Mark Carney’s role in pulling Europe back toward a more realistic strategic footing and away from its longstanding dependence on the United States. Canada, and Carney in particular, appear to be taking an unexpectedly prominent leadership role. Your hosts wonder what Washington’s response will be, and whether the White House will decide that Canada needs to be reminded who’s boss. This episode is brought to you by Fractional Execs Canada. Need help with a serious business problem? As Canadian businesses grow they often require expert help to solve key business challenges. Fractional Execs Canada have assembled a team of experienced strategists, implementors, sales and marketing operators that can help transform your business into a growth engine. They match you with the right person, or team to move your business forward at a pace your business can manage. Talk to Fractional Execs Canada and discover a better, more collaborative way to take your business and your ‘busyness’ in a better direction. Canadian expertise to support the growth of Canadian businesses. Build your business with those that know how. Find them Fractional-Execs.ca. Next, they turn to the proposed Canadian Shield pipeline. On strictly commercial grounds, the project may not make much sense. But Matt and Jen argue that economics may no longer be the primary point. The proposal sends a signal that Canada is prepared to build the infrastructure needed to stand more independently if circumstances require it. That message has value all on its own. As Matt puts it, borrowing from the movie Contact: “Why build one when you can build two at twice the price?” This episode is brought to you by BioCanRx, a federally-funded Canadian not-for-profit research network bringing cutting edge cancer immunotherapy research from Canadian labs to patients in clinical trials –– all in Canada. A drug that can treat your cancer is being tested in a Canadian clinical trial, but can you access it? Depends — where do you live? Clinical trials taking place in Canada usually open sites in major centers with research hospitals. Smaller hospitals face many challenges including having enough know-how to deliver experimental therapies, and administrative, legal, and regulatory responsibilities that come with a trial. There are also data and interoperability issues at hospitals that don’t routinely participate in research. So if you don’t live in a major centre, participating in the trial requires you to relocate there for the duration of treatment –– the cost of the treatment is covered, but the cost of being in the city where it happens is your responsibility. Patient advocacy groups might be able to help with some of those expenses, but this obviously can be a barrier for a lot of Canadians. A therapy might only become available to everyone across Canada if a trial is successful and the drug is approved –– but not necessarily, and maybe not anytime soon. More on that next time. Visit BioCanRx.com to learn more. Finally, the thoroughly hungover shell of Jen Gerson emerges from ten straight days of Calgary Stampede festivities with a political field report. Beneath the parties and pancake breakfasts, she says, the fractures within Canadian conservatism are becoming impossible to ignore. It’s increasingly obvious who is and isn’t willing to speak to whom. What should have been an outstanding month for Alberta Premier Danielle Smith has instead been overshadowed by self-inflicted drama. Meanwhile, Conservative leader Pierre Poilievre continues to struggle against political newcomer Carney. It’s a remarkable — and, in many ways, surprising — dynamic to watch. Wasn't Poilievre supposed to be the political pro who'd mop the floor with the rookie Euro banker? Guess not! All that and more in the latest episode of The Line Podcast. Check out our main page at ReadTheLine.ca and, always and forever, like and subscribe. Programming note: The Line is taking a two-week summer holiday. The podcasts will continue, but barring major news events, our page will be quiet for a few weeks. We need a break! #TheLinePodcast #MarkCarney #CanadianPolitics #CanadaUSRelations #PipelinePolitics #DanielleSmith #PierrePoilievre #CalgaryStampede #Geopolitics #CurrentAffairs

• Chapters

Over the pump

In this episode of On The Line, host Jen Gerson is joined by Andrew Leach, noted energy and environmental economist and professor of economics and law at the University of Alberta, for a conversation about Canadian energy policy at a pivotal moment. This episode is brought to you by BioCanRx, a federally-funded Canadian not-for-profit research network bringing cutting edge cancer immunotherapy research from Canadian labs to patients in clinical trials –– all in Canada. A drug that can treat your cancer is being tested in a Canadian clinical trial, but can you access it? Depends — where do you live? Clinical trials taking place in Canada usually open sites in major centers with research hospitals. Smaller hospitals face many challenges including having enough know-how to deliver experimental therapies, and administrative, legal, and regulatory responsibilities that come with a trial. There are also data and interoperability issues at hospitals that don't routinely participate in research. So if you don’t live in a major centre, participating in the trial requires you to relocate there for the duration of treatment –– the cost of the treatment is covered, but the cost of being in the city where it happens is your responsibility. Patient advocacy groups might be able to help with some of those expenses, but this obviously can be a barrier for a lot of Canadians. A therapy might only become available to everyone across Canada if a trial is successful and the drug is approved –– but not necessarily, and maybe not anytime soon. More on that next time. Visit BioCanRx.com to learn more. Recorded on July 2, 2026, just ahead of two major pipeline announcements, the discussion doesn’t cover the specifics of the federal government’s decision to retrace the TMX route or the proposed Canadian Shield pipeline between Alberta and Sarnia. Instead, Gerson and Leach focus on the broader forces shaping Canada’s energy future. They discuss Prime Minister Mark Carney’s latest Forward Guidance video, the influence of the United States on Canadian energy policy and markets, the promise and limitations of carbon capture and storage, and the political significance of the new Memorandum of Understanding between Alberta and Ottawa. Throughout the conversation, Leach offers his perspective on what has changed — and what hasn’t — in the relationship between governments, industry, and the public. This episode is also brought to you by the Forest Products Association of Canada. Canada’s forest products sector is not asking Ottawa to start over. The federal government has heard the advice. It has recognized the challenges. And it has put a plan on the table. Now the test is action. That means clearing made-in-Canada barriers: regulatory duplication, transportation bottlenecks, and uncertainty around predictable access to manage our forests. It means working with provinces to protect communities from wildfire risk and giving companies the confidence to invest here at home. Nearly 200,000 Canadians working in this sector are looking for results. The playbook is written. Now Ottawa needs to deliver. Learn more at fpac.ca. The episode also asks a larger question: after decades of political conflict over pipelines, is Canada finally entering a new era? Could this be the beginning of a more grounded conversation about the country’s oil and gas sector, one that focuses less on symbolic battles and more on practical questions of economics, infrastructure, and national interest? This episode is also brought to you by Cameco. In nuclear energy, timelines and costs matter. Incomplete designs carry real risk of delays and cost overruns. That’s why the AP1000 reactor is the right choice for Canada: it is already operating today and ready now to deliver the power we need, with 100 percent Canadian ownership and strong participation from Canadian suppliers. If we are serious about building Canada and powering it on time and on budget, the choice is clear. The AP1000 reactor is the only option that delivers. To learn more, visit ap1000.cameco.com. If you enjoyed the episode, be sure to share it, and as always, like and subscribe to us on your podcast or video app of choice. Be sure to check out our main page at ReadTheLine.ca. #OnTheLine #AndrewLeach #Energy #Pipelines #TMX #OilAndGas #MarkCarney #Alberta #CanadaPolitics #JenGerson

• Chapters

Carney gets a pipeline deal. Now let's build the damn thing

In the latest episode of The Line Podcast, recorded on July 3rd, 2026, Matt Gurney and Jen Gerson begin with the biggest political news of the week: a pipeline deal. Prime Minister Mark Carney has struck agreements with both Alberta and British Columbia to move another pipeline project forward. Your hosts discuss the proposed route, which closely follows the existing Trans Mountain corridor, the political wheeling and dealing that made the agreement possible, and what it could mean for Alberta’s upcoming referendum. Matt also can’t help asking an obvious question: since this was always the logical outcome, why did it take so long? Was there a genuine engineering obstacle behind the scenes, or are Canadian governments simply incapable of moving quickly? This episode is brought to you by Fractional Execs Canada. Need help with a serious business problem? As Canadian businesses grow they often require expert help to solve key business challenges. Fractional Execs Canada have assembled a team of experienced strategists, implementors, sales and marketing operators that can help transform your business into a growth engine. They match you with the right person, or team to move your business forward at a pace your business can manage. Talk to Fractional Execs Canada and discover a better, more collaborative way to take your business and your ‘busyness’ in a better direction. Canadian expertise to support the growth of Canadian businesses. Build your business with those that know how. Find them Fractional-Execs.ca. Next, they turn to another round of comments from U.S. Ambassador Pete Hoekstra. After a brief discussion of CUSMA, the conversation shifts to Hoekstra’s remarks about the Gordie Howe International Bridge. Your hosts aren’t especially worried. In fact, they think they have the perfect strategy: troll the White House until it becomes so embarrassed that it can’t wait to open the bridge just to make the pain stop. Their suggestions include live episodes of The View from the bridge deck, Bruce Springsteen concerts, and, naturally, renaming it the Barack Hussein Obama Nobel Peace Prize Bridge of Friendship. This episode is also brought to you by BioCanRx, a federally-funded Canadian not-for-profit research network focused on cutting-edge immunotherapy research that they’re helping Canadian researchers bring from labs to patients in clinical trials –– all in Canada.Clinical trials are the way new drugs, including immunotherapies, are tested in patients around the world. Health Canada, our national regulator, reviews and approves all Clinical Trial Applications, or CTAs, returning a decision within 30 days –– a similar turnaround time as the US FDA and other major jurisdictions. To submit a complete CTA, applicants need to provide hundreds –– sometimes thousands –– of pages of data showing that a drug has a compelling chance of providing benefit, that it can be manufactured consistently, and that it’s safe to administer to trial participants. This is especially hard for Canadian researchers because scientific studies that generate the necessary data aren't supported by many federal grants, which usually prioritize originality over real world impact. BioCanRx helps Canadian researchers succeed in the CTA process, and so far they’ve gotten 16 therapies to trial. To learn more, visit BioCanRx.com. Finally, Matt attempts to diagnose what has gone wrong with Canada’s civic culture and even ventures a possible cure. Toronto, he argues, needs its own version of the Calgary Stampede, and Canada more broadly needs something capable of genuinely uniting the country. The trouble is that neither host can think of an obvious candidate. They conclude that Canada — and Toronto in particular — has become too self-conscious and too embarrassed by its own past to celebrate it with much enthusiasm. All that and more in the latest episode of The Line Podcast. Check out our main page at ReadTheLine.ca. #TheLinePodcast #MarkCarney #PipelinePolitics #CanadianPolitics #CanadaUSRelations #CUSMA #GordieHoweBridge #AlbertaPolitics #PoliticalAnalysis #CurrentAffairs

• Chapters

Frontlines of Canadian Emergency Care

In this episode of On The Line, host Matt Gurney sits down with Dr. Brian Goldman, veteran emergency physician at Mount Sinai Hospital in Toronto and author of The Casino Shift: Stories from an ER on the Edge, for a candid conversation about the state of emergency medicine in Canada. (You can find it on Indigo's website, or, if you prefer, on Amazon.) This episode is brought to you by BioCanRx, a federally-funded Canadian not-for-profit research network bringing cutting edge cancer immunotherapy research from Canadian labs to patients in clinical trials –– all in Canada. Clinical trials are the way new drugs, including immunotherapies, are tested in patients around the world. It’s up to the developer of the drug to decide whether they want to trial it in Canada –– and many do. Health Canada, our national regulator, reviews and approves all Clinical Trial Applications, or CTAs, returning a decision within 30 days –– a similar turnaround time as the U.S. FDA and other major jurisdictions. If they approve, and if the trial receives research ethics approval, it can start enrolling Canadian patients. To submit a complete CTA, applicants must provide hundreds –– sometimes thousands –– of pages of data showing that a drug has a compelling chance of providing benefit, that it can be manufactured consistently, and that it’s safe to administer to trial participants. This is especially hard for Canadian researchers because scientific studies that generate the necessary data aren't supported by many federal grants, which usually prioritize originality over real-world impact. BioCanRx helps Canadian researchers succeed in the CTA process, and so far they’ve gotten 16 therapies to trial. But once a trial starts, how can Canadians learn about it, and where can they access it? That question and more next time. Visit BioCanRx.com to learn more. Drawing on decades in one of the country’s busiest emergency departments, Goldman explains why today’s ERs are under extraordinary strain, and why the problems extend far beyond long wait times. They discuss the pressures facing doctors, nurses, and patients alike, the growing mismatch between demand and capacity, and why the old problem of hallway medicine is increasingly giving way to something even worse: chair medicine, with patients waiting for hours in chairs because there simply isn’t anywhere else to put them. The conversation also explores the human side of emergency medicine. Goldman reflects on the emotional and psychological toll of working in an overwhelmed system, the stories that inspired The Casino Shift, and what keeps health-care workers coming back despite the mounting pressures. This episode is also brought to you by the Forest Products Association of Canada. A stronger forest industry can help build Canada strong. We need more homes, faster and more affordably, and Canadian wood can be part of the solution. Light-frame construction, mass timber, modular systems, and other modern building methods can support housing, lower embodied carbon, and strengthen domestic supply chains. The same opportunity exists in schools, health facilities, community buildings, and public infrastructure. When Canada builds, Canadian materials and Canadian workers must be part of the plan. Learn more at fpac.ca. Finally, Matt and Goldman tackle one of the most contentious questions in Canadian health care. Goldman argues that it’s time for a calm, respectful, and evidence-based discussion about whether private options should play a larger role within Canada’s publicly funded system. Rather than treating the issue as ideological warfare, he makes the case for focusing on what actually improves patient care, and how other jurisdictions are approaching this problem. It’s a frank discussion about the realities facing Canada’s healthcare system, the people trying to hold it together, and the difficult choices that may lie ahead. This episode is also brought to you by Cameco. In nuclear energy, timelines and costs matter. Incomplete designs carry real risk of delays and cost overruns. That’s why the AP1000 reactor is the right choice for Canada: it is already operating today and ready now to deliver the power we need, with 100 percent Canadian ownership and strong participation from Canadian suppliers. If we are serious about building Canada and powering it on time and on budget, the choice is clear. The AP1000 reactor is the only option that delivers. To learn more, visit ap1000.cameco.com. If you enjoyed the episode, be sure to share it, and as always, like and subscribe to us on your podcast or video app of choice, and check out our main page at ReadTheLine.ca. #OnTheLine #BrianGoldman #Healthcare #EmergencyMedicine #CanadianHealthcare #MountSinai #TheCasinoShift #PublicHealth #CanadaPolitics #MattGurney

• Chapters

Carney makes the easy call to fix our most symbolic national embarrassment

In today’s episode of The Line Podcast, recorded on June 26th, 2026, Matt Gurney and Jen Gerson begin with a rare moment of joy. After decades of delay and political paralysis, there is finally a plan to deal with 24 Sussex Drive. Your hosts don’t love every aspect of it, but they’re so relieved that someone has finally decided to do something that they’re prepared to celebrate. Now comes the hard part: not finding a way to mess it up. This episode of The Line Podcast is brought to you by Cameco. In nuclear energy, timelines and costs matter. Incomplete designs carry real risk of delays and cost overruns. That’s why the AP1000 reactor is the right choice for Canada: it is already operating today and ready now to deliver the power we need, with 100 percent Canadian ownership and strong participation from Canadian suppliers. If we are serious about building Canada and powering it on time and on budget, the choice is clear. The AP1000 reactor is the only option that delivers. To learn more, visit ap1000.cameco.com. From there, they turn to the tragic shooting in Montreal that claimed the life of another police officer. Beyond the immediate heartbreak, your hosts focus on two broader issues. First, they argue that the media should have published the shooter’s manifesto. By choosing not to do so, they contend, some early reporting ended up being incomplete or inaccurate. Second, they discuss the rush by commentators across the political spectrum to comb through the manifesto looking for evidence that the attacker perfectly represented their opponents — or, failing that, had nothing whatsoever to do with their own side. Matt and Jen argue that modern terrorism is often ideologically incoherent, and that treating every attack as an opportunity for partisan point-scoring will only make it harder to understand and prevent future violence. This episode is also brought to you by Fractional Execs Canada. Need help with a serious business problem? As Canadian businesses grow they often require expert help to solve key business challenges. Fractional Execs Canada have assembled a team of experienced strategists, implementors, sales and marketing operators that can help transform your business into a growth engine. They match you with the right person, or team to move your business forward at a pace your business can manage. Talk to Fractional Execs Canada and discover a better, more collaborative way to take your business and your ‘busyness’ in a better direction. Canadian expertise to support the growth of Canadian businesses. Build your business with those that know how. Find them Fractional-Execs.ca. Finally, Jen makes a wardrobe change that only video viewers will fully appreciate before walking Matt through the increasingly strange politics of the Calgary Stampede. What was once simply Alberta’s biggest annual celebration is now becoming another front in an ongoing proxy war between competing factions within the broader conservative movement. This episode is also brought to you by BioCanRx, a federally-funded Canadian not-for-profit research network, which helps bring cutting edge cancer immunotherapy research from Canadian scientists from labs to patients in clinical trials –– all in Canada. Cancer is very good at evading your immune system. But in some tumors, researchers find cancer-killing immune cells called tumour infiltrating lymphocytes, or TILs. They get inside the tumour and start fighting — but they’re outnumbered and ill equipped. Researchers in Canada and around the world are studying techniques to extract them from a tumour and multiply them in a lab. Once they number in the millions, they’re injected back into the tumour to do more damage. Research into this line of attack against cancer is ongoing. There are plenty of unanswered questions, and we're working hard to answer them. Learn more about this and other critical work at BioCanRx.com. All that and more in the latest episode of The Line Podcast. Check out our main page at ReadTheLine.ca, and as ever, like and subscribe. #TheLinePodcast #CanadianPolitics #24Sussex #Montreal #CalgaryStampede #AlbertaPolitics #PoliticalAnalysis #CanadianMedia #LawEnforcement #CurrentAffairs

• Chapters

Carney condo bailout? Not quite

In today’s episode of On The Line, host Matt Gurney is joined by two guests for conversations about housing, politics, and why governments sometimes struggle to explain themselves. This episode is brought to you by BioCanRx. When your immune system recognizes that cancer is a problem, but can’t kill it, can science help? This summer we’re partnering with BioCanRx, a federally-funded Canadian not-for-profit research network, to learn about cutting edge cancer immunotherapy research that they’re helping Canadian researchers bring from labs to patients in clinical trials –– all in Canada. One of the reasons cancers are so destructive is because they find ways to evade your immune system. But in some tumours, researchers find cancer-killing immune cells called "tumour infiltrating lymphocytes," or TILs. These are like infantry grunts choosing to stand their ground during the final fight in a superhero movie. They get inside the tumour and start fighting – –but they’re outnumbered and ill equipped. They need reinforcements. Researchers in Canada and around the world are studying techniques to extract them from a tumour and multiply them in a lab environment. Once they number in the millions, they're sent back into the fight. Research into this line of attack against cancer is ongoing, and there are plenty of questions — we'll be covering more of them over the course of the summer. Go to BioCanRx.com to learn more about these new ways of fighting cancer. First up is Mike Moffatt of the Missing Middle Initiative and co-host of the Missing Middle Podcast. He joins Matt to discuss the much-debated “condo bailout” and why, despite the label, it isn’t actually a condo bailout at all. Moffatt argues that the government has done itself no favours by communicating the policy so poorly, and walks listeners through what the plan is — and what it isn’t. The conversation then broadens into a look at the state of housing in Canada more generally. There are some signs of progress, but the underlying challenges remain enormous, and Moffatt explains why solving them will require much more than a handful of headline-grabbing announcements. This episode is also brought to you by the Forest Products Association of Canada. A stronger forest industry depends on getting goods to market. Forest products move by truck, rail, and ship, and reliability matters. When costs rise or shipments stall, mills, workers, customers, and communities all feel the impact. Stronger trade corridors, better rail performance, labour stability, and reliable transportation should be treated as core parts of Canada’s productivity agenda. For a sector rooted in communities and connected to global markets, transportation is transformation. Learn more at FPAC.ca. Then Matt is joined by Andrew MacDougall of Trafalgar Strategy for a look across the Atlantic at the increasingly turbulent state of British politics. They discuss the struggles of now-outgoing Prime Minister Keir Starmer, the rise of Andy Burnham as a potential future national leader, and why so many observers now see the United Kingdom as becoming increasingly difficult to govern. MacDougall argues that the country’s problems run deeper than any one politician or party, and offers his own diagnosis of what has gone wrong. It’s a pair of conversations about institutions under strain, political communication, and the challenge of governing in an era when public patience is increasingly in short supply. This episode is also brought to you by Cameco. In nuclear energy, timelines and costs matter. Incomplete designs carry real risk of delays and cost overruns. That’s why the AP1000 reactor is the right choice for Canada: it is already operating today and ready now to deliver the power we need, with 100 percent Canadian ownership and strong participation from Canadian suppliers. If we are serious about building Canada and powering it on time and on budget, the choice is clear. The AP1000 reactor is the only option that delivers. To learn more, visit ap1000.cameco.com. Check out our main page at ReadTheLine.ca, and as always, like and subscribe. #OnTheLine #Housing #MikeMoffatt #MissingMiddle #CanadaHousing #KeirStarmer #AndyBurnham #UKPolitics #AndrewMacDougall #MattGurney

• Chapters

Why does America hate us, we're poor

In the latest episode of The Line Podcast, recorded on June 19th, 2026, Matt Gurney and Jen Gerson begin with a foreign affairs roundup. Prime Minister Mark Carney heads to Ireland and France to strengthen ties with Europe while also trying to maintain a workable relationship with Donald Trump. Meanwhile, U.S. Defense Secretary Pete Hegseth visits NATO and delivers some pointed criticism of allies that, while not directed at Canada by name, certainly sounds familiar. Your hosts also discuss the aftermath of America’s confrontation with Iran. Matt argues that the United States has, in practical terms, suffered a defeat — an embarrassing outcome for Trump, but perhaps a useful lesson for the rest of us about the limits of military power. This episode is brought to you by Fractional Execs Canada. Need help with a serious business problem? As Canadian businesses grow they often require expert help to solve key business challenges. Fractional Execs Canada have assembled a team of experienced strategists, implementors, sales and marketing operators that can help transform your business into a growth engine. They match you with the right person, or team to move your business forward at a pace your business can manage. Talk to Fractional Execs Canada and discover a better, more collaborative way to take your business and your ‘busyness’ in a better direction. Canadian expertise to support the growth of Canadian businesses. Build your business with those that know how. Find them Fractional-Execs.ca. Next, they take a quick tour through the provinces. Matt is increasingly worried that Doug Ford could inadvertently throw Canada-U.S. negotiations into chaos, and explains why. Jen provides an update from Alberta, where the political situation remains bizarre. By the end of the segment, both hosts arrive at a grim conclusion: the incentives facing almost every major political actor now reward escalation, confrontation, and nastiness. That rarely ends well. This episode of The Line Podcast is also brought to you by BioCanRx, a federally-funded Canadian not-for-profit research network helping Canadian researchers bring treatments from labs to patients in clinical trials –– all in Canada. Every day, your immune system finds and destroys different types of threats –– both external invaders like viruses, and internal dangers like pre-cancerous cells in your own body. But cancer can sometimes evade detection. Researchers are working to identify flags found on cancer cells, called antigens. By training your immune system to recognize these antigens, immunotherapy can help your immune system destroy cancer. In addition to funding clinical trials, BioCanRx supports research teams who identify these cancer antigens, and find new ways to target them. Many challenges remain — and we’re working on solving them. You’ll hear more over the summer. For now, go to BioCanRx.com to learn more. Finally, Jen disappears down one of her trademark rabbit holes and emerges with a sweeping explanation of how she came to fully appreciate the sheer economic power of the United States. Somehow, this journey involves gas pumps, brisket, beef jerky, the Soviet Union, and the defeat of Imperial Japan in 1945. Your hosts find themselves reflecting on what American economic dominance really means, why it has proven so durable, and what lessons Canada should draw from it as we navigate an increasingly uncertain world. All that and more in the latest episode of The Line Podcast. Check us out on our main page, ReadTheLine.ca. #TheLinePodcast #MarkCarney #DonaldTrump #CanadaUSRelations #AlbertaPolitics #DougFord #CanadianPolitics #Geopolitics #NATO #CurrentAffairs

• Chapters